缺氧驱动的蛋白质稳定性扰动和癌症治疗脆弱性
Manvi Sharma1, Tushar Singh Barwal2, Neha2
1Freie Universität Berlin, Berlin, Germany.
Advances in protein chemistry and structural biology
|November 27, 2025
概括
固体瘤中的缺氧会导致蛋白质错折,并触发未折叠蛋白质反应 (UPR). 癌细胞利用这种UPR进行适应,推动瘤的进展和治疗耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞应激反应的应激反应
背景情况:
- 固体瘤表现出混乱的结构和异常的血管系统,导致缺氧和无氧区域.
- 缺氧稳定了缺氧诱导因素 (HIF-1和HIF-2),导致癌症的进展.
- 缺氧瘤区域破坏蛋白质稳定,影响内质网膜蛋白质折叠.
研究的目的:
- 详细说明缺氧如何调节癌症中的蛋白质错折.
- 解释由缺氧诱导的蛋白质错折驱动的癌细胞适应机制.
- 概述低氧驱动癌症进展的潜在治疗点.
主要方法:
- 对癌症中缺氧,蛋白质稳定和未折叠蛋白质反应 (UPR) 的现有文献的综述.
- 分析ER传感器 (PKR类ER激酶,内醇要求酶1,激活转录因子6) 在低氧诱导的UPR中的作用.
- 检查证据,将缺氧诱导的错误折叠蛋白与瘤进展,基因组不稳定性和瘤信号传递联系起来.
主要成果:
- 低氧作用为压力因素,导致ER中错误折叠的蛋白质积累.
- 癌细胞劫持了UPR以增强代谢灵活性,免疫逃避和抵抗力.
- 缺氧诱导的错误折叠蛋白质通过基因组不稳定性和失调的信号传递促进瘤的进展.
结论:
- 缺氧严重影响癌细胞通过蛋白质错折和UPR调节的适应.
- 了解这些机制揭示了固体瘤的关键治疗标.
- 针对缺氧诱导的蛋白质稳定性障碍为癌症治疗提供了一个有前途的策略.
相关概念视频
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K


